Safety and Efficacy of the 10-Day Melarsoprol Schedule for the Treatment of Second Stage Rhodesiense Sleeping Sickness

PLoS Neglected Tropical Diseases

Volumn 6, Issue 8, 2012, Pages

  Kuepfer, Irene ^a,b   Schmid, Caecilia ^a,b   Allan, Mpairwe ^c   Edielu, Andrew ^c   Haary, Emma P ^d   Kakembo, Abbas ^e   Kibona, Stafford ^f   Blum, Johannes ^a,b   Burri, Christian ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Lwala Hospital   (Uganda)

^d Kaliua Health Centre   (Tanzania)

^e MINISTRY OF HEALTH   (Uganda)

^f NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

MELARSOPROL; PARACETAMOL; PREDNISONE; STEROID; SURAMIN;

ADOLESCENT; ADULT; AFRICAN TRYPANOSOMIASIS; AGED; ARTICLE; BRAIN DISEASE; CEREBROSPINAL FLUID ANALYSIS; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FATALITY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; INCIDENCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALARIA; MALE; MICROSCOPY; MULTICENTER STUDY; NAUSEA; PRESCHOOL CHILD; PROSPECTIVE STUDY; PSYCHOSIS; RELAPSE; SCHOOL CHILD; SKIN MANIFESTATION; TREATMENT OUTCOME; TRYPANOSOMA RHODESIENSE; VOMITING;

ADOLESCENT; ADULT; AGED; BRAIN DISEASES; CHILD; DRUG ADMINISTRATION SCHEDULE; ENDEMIC DISEASES; FEMALE; HUMANS; MALE; MELARSOPROL; MIDDLE AGED; SURAMIN; TANZANIA; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMIASIS, AFRICAN; UGANDA;

EID: 84865966527     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001695     Document Type: Article

References (39)

1. Checchi F, Filipe JA, Haydon DT, Chandramohan D, Chappuis F, (2008) Estimates of the duration of the early and late stage of gambiense sleeping sickness. BMC Infect Dis 8: 16.
2. Odiit M, Kansiime F, Enyaru JC, (1997) Duration of symptoms and case fatality of sleeping sickness caused by Trypanosoma brucei rhodesiense in Tororo, Uganda. East Afr Med J 74 (12): 792-5.
3. WHO (1998) Control and surveillance of African trypanosomiasis. Geneva: WHO.
4. WHO (2006) Human African trypanosomiasis (sleeping sickness): epidemiological update. Weekly epidemiological record TRS881: 69-80.
5. Bales JD (1988) African Trypanosomiasis. In: Hunter's Tropical Medicine. 7 ed. Strickland GT, editor. Philadelphia: Saunders Company. 617-28.
6. Odiit M, Coleman PG, Liu WC, McDermott JJ, Fevre EM, et al. (2005) Quantifying the level of under-detection of Trypanosoma brucei rhodesiense sleeping sickness cases. Trop Med Int Health 10 (9): 840-9.
7. Fevre EM, Coleman PG, Odiit M, Magona JW, Welburn SC, et al. (2001) The origins of a new Trypanosoma brucei rhodesiense sleeping sickness outbreak in eastern Uganda. Lancet 358 (9282): 625-8.
8. Fevre EM, Odiit M, Coleman PG, Woolhouse ME, Welburn SC, (2008) Estimating the burden of Rhodesiense sleeping sickness during an outbreak in Serere, eastern Uganda. BMC Public Health 8: 96.
9. Kaare MT, Picozzi K, Mlengeya T, Fevre EM, Mellau LS, et al. (2007) Sleeping sickness-a re-emerging disease in the Serengeti? Travel Med Infect Dis 5 (2): 117-24.
10. Iten M, Matovu E, Brun R, Kaminsky R, (1995) Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO). Trop Med Parasitol 46 (3): 190-4.
11. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, et al. (2009) Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374 (9683): 56-64.
12. WHO (2009) WHO Model Lists of Essential Medicines. 16th ed. WHO. 43.
13. Friedheim EAH, (1949) Mel B in the treatment of human trypanosomiasis. American Journal of Tropical Medicine and Hygiene 29: 173-80.
14. Pepin J, Donelson JE (1999) African Trypanosomiasis (Sleeping Sickness). In: Tropical Infectious Diseses; Principles, Pathogens & Practise. 1 ed. Guerrant RL, Walker DH, Weller PF, editors. Philadelphia: Churchill Livistone. 774-84.
15. Pepin J, Milord F, Khonde AN, Niyonsenga T, Loko L, et al. (1995) Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 89 (1): 92-7.
16. Arroz JO, (1987) Melarsoprol and reactive encephalopathy in Trypanosoma brucei rhodesiense. Trans R Soc Trop Med Hyg 81 (2): 192.
17. Onyango RJ, Bailey NM, Okach RW, Mwangi EK, Ogada T, (1969) Encephalopathy during treatment of human trypanosomiasis. EATRO report.
18. Apted FIC, (1980) Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the eastern hemisphere. Pharmacology and Therapeutics 11: 391-413.
19. Burri C, Baltz T, Giroud C, Doua F, Welker HA, et al. (1993) Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy 39 (4): 225-34.
20. Burri C, Blum J, Brun R, (1995) Alternative application of melarsoprol for treatment of T. b. gambiense sleeping sickness. Preliminary results. Annales de la Société Belge de Médecine Tropicale 75 (1): 65-71.
21. Burri C, Nkunku S, Merolle A, Smith T, Blum J, et al. (2000) Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 355 (9213): 1419-25.
22. Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C, (2004) Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 364 (9436): 789-90.
23. Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, et al. (2005) Effectiveness of a 10-Day Melarsoprol Schedule for the Treatment of Late-Stage Human African Trypanosomiasis: Confirmation from a Multinational Study (Impamel II). J Infect Dis 191 (11): 1922-31.
24. Woo PT, (1969) The haematocrit centrifuge for the detection of trypanosomes in blood. Can J Zool 47 (5): 921-3.
25. Blum J, Nkunku S, Burri C, (2001) Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 6 (5): 390-400.
26. Kuepfer I, Hhary EP, Allan M, Edielu A, Burri C, et al. (2011) Clinical presentation of T.b. rhodesiense sleeping sickness in second stage patients from Tanzania and Uganda. PLoS Negl Trop Dis 5 (3): e968.
27. Pepin J, Milord F, Guern C, Mpia B, Ethier L, et al. (1989) Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet 1 (8649): 1246-50.
28. McGeary RP, Bennett AJ, Tran QB, Cosgrove KL, Ross BP, (2008) Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem 8 (13): 1384-94.
29. Seixas J, (2004) Investigations on the encephalopathic syndrome during melarsoprol treatment in human African trypanosomiasis [PhD Thesis]. Basel.
30. Legros D, Evans S, Maiso F, Enyaru JCK, Mbulamberi D, (1999) Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene 93: 439-42.
31. Matovu E, Iten M, Enyaru JC, Schmid C, Lubega GW, et al. (1997) Susceptibility of Ugandan Trypanosoma brucei rhodesiense isolated from man and animal reservoirs to diminazene, isometamidium and melarsoprol. Trop Med Int Health 2 (1): 13-8.
32. Stanghellini A, Josenando T, (2001) The situation of sleeping sickness in Angola: a calamity. Tropical Medicine and International Health 6 (5): 330-4.
33. Robays J, Bilengue MMC, Stuyft PVd, Boelaert M, (2004) The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo. Tropical Medicine & International Health 9: 542.
34. Apted FI, (1957) Four years' experience of melarsen oxide/BAL in the treatment of late-stage Rhodesian sleeping sickness. Trans R Soc Trop Med Hyg 51 (1): 75-86.
35. Foulkes JR, (1996) Metronidazole and suramin combination in the treatment of arsenical refractory Rhodesian sleeping sickness-a case study. Trans R Soc Trop Med Hyg 90 (4): 422.
36. Bales J, Harrsion S, Mbwabi D, (1988) The treatment of Rhodesian sleeping sickness. A review of 46 cases. Manuscript pp. 11.
37. Robertson DH, (1963) The treatment of sleeping sickness (mainly due to Trypanosoma rhodesiense) with melarsoprol. I. Reactions observed during treatment. Trans R Soc Trop Med Hyg 57: 122-33.
38. Kibona SN, Matemba L, Kaboya JS, Lubega GW, (2006) Drug-resistance of Trypanosoma b. rhodesiense isolates from Tanzania. Trop Med Int Health 11 (2): 144-55.
39. African Union, Resources IBfA (2010) 30th International scientific council for trypanosomiasis research and control conference ISCTRC. Reports and recommendations. Kampala: International scientific council for trypanosomiasis research and control; 21-25.09.2010.